Evommune Inc. EVMN
8.49
(0.31)
(3.52%)
as of 25 Sep
- Market cap
- $309.9M
- P/E
- 0.0×
Follow EVMN
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+4 more TTM periods Free account |
0.00% | 0.00% | 0.00% | (141.99%) | |
| (133.69%) | (61.23%) | (47.13%) | (62.71%) | ||
ROIC |
0.00% | (89.61%) | (60.08%) | (82.46%) | |
Return on Tangible Assets |
(77.95%) | (50.43%) | (36.73%) | (50.25%) | |
Free Cash Flow per Share |
(50.65) | (12.51) | (2.39) | (2.07) | |
Free Cash Flow |
(78.25) | (76.76) | (80.36) | (74.65) | |
Capital Expenditures |
— | (0.32) | (0.32) | (0.50) | |
Piotroski F-Score |
0.00 | 0.00 | 0.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
73.08% | (21.54%) | (15.50%) | (15.49%) | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.38 | 1.11 | 1.05 | 0.78 | |
Depreciation/Fixed assets |
1.47 | 1.40 | 0.61 | 0.40 | |
Capex/Depreciation |
0.00 | (0.23) | (0.32) | (0.76) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(50.65) | (12.46) | (2.38) | (2.05) | |
Capex per Share |
0.00 | (0.05) | (0.01) | (0.01) | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates